Replies to post #31772 on RespireRx Pharmaceuticals Inc (RSPI)

[enemem]

All this is doable, particularly in the context of the FDA's own request for development of treatment for this condition.

[atheroprevent]

>>if the patient is an RD crisis, the doctor won't be able to easily 'try out something new'. He's going to have to use Narcan immediately to save the patient's life.<<

It will not be that difficult, Gfp. The postop RD patient is not in crisis. His respiration is controlled manually by the anesthesiologist, if need be, temporarily in the transition area of the recovery room. Narcan would be reserved for a rare true crisis where airway control is lost by the anesthesiologist, and I would agree such a patient would not safely qualify for any randomized trial.

The patients qualifying for such study, would be those that are unable to sustain independent respiration. They could be randomized, and if their condition extended beyond a defined time period(15min?), they could even be crossed over, to the other arm of the study. Interestingly they could include or exclude SA patients (since they would be predisposed to RD). I do see a problem in consenting a large number of preop patients, with a low likelihood of qualifying for the study after the surgery. JMO.